Leading companies in gene editing and biotechnology

Prime Medicine is a developer of gene-editing technology, specifically prime editing, which allows for 'search-and-replace' genetic edits with fewer off-target effects. This technology is entering a broader 'human validation' phase in 2026.

CRISPR Therapeutics is a leader in CRISPR/Cas9-based therapies, recognized for its advancements in personalized medicine and significant clinical trial progress. The company's proprietary platform is crucial for treating conditions like beta-thalassemia and autoimmune diseases.

Intellia Therapeutics is at the forefront of CRISPR/Cas9-based therapies, with a strong pipeline for genetic disorders like transthyretin amyloidosis and hereditary angioedema. Their collaborations and late-stage clinical studies highlight their impact.

Beam Therapeutics is a leader in CRISPR base editing, a safer form of gene editing that modifies single DNA letters without double-stranded breaks. Their progress in treating severe sickle cell disease showcases their innovative approach.

Verve Therapeutics is revolutionizing cardiovascular disease treatment with single-course gene-editing therapies, targeting genes to control blood lipid levels. Their significant deal with Eli Lilly underscores their potential to replace daily medication.

eGenesis is a pioneer in xenotransplantation, using gene editing to enable the transplantation of genetically modified pig kidneys into humans. Their record-breaking success in sustaining patients highlights their groundbreaking work.

Sarepta Therapeutics is a key player in gene therapy, with an FDA-approved drug, Elevidys, and ongoing advancements in RNA-based therapies. Their continued clinical trials for Duchenne muscular dystrophy demonstrate their commitment to patient care.

Elevate Bio offers a comprehensive cell and gene therapy platform, providing expertise in the design, development, and manufacturing of various therapies. Their recent certification underscores their robust capabilities in the field.

Thermo Fisher Scientific holds a dominant position in the gene editing market, offering comprehensive portfolios of CRISPR kits, reagents, and advanced software solutions. Their integrated approach streamlines gene editing workflows for research and therapeutic development.

Regeneron Pharmaceuticals leverages advanced gene editing technologies in drug discovery and therapeutic development, supporting CRISPR-based screening and genetic target validation. Their partnership with Intellia Therapeutics highlights their commitment to innovation.

Mammoth Biosciences is developing a groundbreaking CRISPR-based illness detection platform, utilizing Cas12 and Cas13 proteins for diagnostics and genome editing therapeutics. Their work is creating a new class of diagnostics across multiple industries.

Scribe Therapeutics develops molecular engineering solutions for CRISPR-based genetic medicine, utilizing their proprietary CRISPR-Cas X-Editor technology. Their collaboration with Eli Lilly and Company demonstrates significant progress in gene-editing programs.

Micro CRISPR focuses on AI-driven gene editing and programmable biology, embedding AI directly into the iterative cycle of gene editing for faster optimization. Their well-capitalized platform and clinical-stage assets position them as a significant innovator.

Aurora Therapeutics, launched in early 2026, is tackling the problem of scale in gene editing by building a reusable platform. Their aim is to make personalized treatments more scalable and cost-effective, benefiting smaller patient populations.

Basecamp Research is recognized for its innovative use of AI and extensive genomic data to design custom gene-editing enzymes. They have significantly expanded their proprietary genomic dataset, enhancing their capabilities.